NasdaqGS:MDGLBiotechs
What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders
Madrigal Pharmaceuticals recently reported first-quarter 2026 results, posting a net loss of US$94.39 million, or US$3.25 per share, compared with a loss of US$73.24 million, or US$2.61 per share, a year earlier.
Alongside these wider losses, the company highlighted strong year-on-year revenue growth from Rezdiffra and reinforced its MASH-focused story ahead of a May 2026 Fierce Biotech Week presentation featuring its Chief Medical Officer.
Next, we’ll examine how Rezdiffra’s early...